MPR18h
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
Pharmaceutical Technology on MSN1d
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
MedPage Today1d
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
BioWorld1d
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars
Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...
Fierce Pharma1d
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR
Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...
Zacks Investment Research on MSN1d
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Shares of Soleno Therapeutics SLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR ...